Aptamer Screening via HT-SELEX (High-Throughput Systematic Evolution of Ligands by Exponential Enrichment) is the modern, powerful method for discovering aptamers. Let's break down what this service entails, its process, advantages, and key considerations. What is an Aptamer? First, a quick reminder: Aptamers are single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (proteins, small molecules, cells, viruses) with high affinity and specificity, analogous to antibodies. They are often called "chemical antibodies." What is HT-SELEX? Traditional SELEX is iterative and low-throughput. HT-SELEX supercharges this process by integrating: Next-Generation Sequencing (NGS): To analyze the entire aptamer pool at each round. Advanced Bioinformatics: To identify binding motifs and track enrichment. Automation: Using robotics for partitioning (e.g., magnetic beads, microfluidics) to increase throughput and reproducibility. This results in a faster, more efficient, and data-driven screening process. Standard HT-SELEX Service Workflow A typical service provider will follow these steps: 1. Project Design & Library Synthesis Target Preparation: You provide the target (recombinant protein, small molecule conjugate, whole cell, etc.). Its purity and stability are critical. Library Design: A randomized oligonucleotide library is synthesized (typically 10^14 - 10^15 unique sequences). Libraries can be DNA, RNA, or modified nucleotides (e.g., SOMAmers) for enhanced stability and affinity. 2. The Selection Rounds (Cycles of…
What is Counter-SELEX? First, a quick recap of SELEX (Systematic Evolution of Ligands by EXponential Enrichment): SELEX is an iterative process to isolate specific DNA or RNA aptamers from a vast random library (10^14 - 10^15 sequences) that bind tightly to a target molecule (e.g., a protein, small molecule, cell). Counter-SELEX is a powerful refinement to this process. Its core purpose is to improve specificity by negative selection. How it works: During or between rounds of positive selection (binding to the desired target), the oligonucleotide pool is exposed to one or more counter-targets. The Goal: Sequences that bind to these counter-targets are deliberately removed or depleted from the pool. Only sequences that bind specifically to the desired target and not to the closely related counter-targets are carried forward. Common Counter-Targets: Structural analogs: For a small-molecule drug, you might use its inactive metabolite or a similar drug from the same class. Protein isoforms or family members: To develop an aptamer for a specific kinase, you'd use other kinases from the same family as counter-targets. Immobilization matrix: If the target is immobilized on beads, pre-incubating the library with "blank" beads removes matrix binders. Related cell types: For a cell-specific aptamer (e.g., cancer vs. healthy), the healthy cells are used as the counter-target. What Does a…
What is Subtractive SELEX? It is a specialized version of SELEX used to generate aptamers (single-stranded DNA or RNA oligonucleotides) that bind with high affinity and specificity to a target of interest (e.g., a protein, cell, small molecule) while actively excluding binding to closely related non-targets (e.g., a non-pathogenic vs. pathogenic strain, a healthy vs. cancerous cell, or a target in a complex mixture). The "subtractive" step removes sequences that bind to unwanted counter-targets, ensuring the final aptamer pool is highly specific. Core Workflow of a Subtractive SELEX Service A typical service follows these key stages: 1. Project Design & Library Synthesis Client Consultation: Defining the target of interest (e.g., recombinant protein, whole cell) and the critical counter-target(s) for subtraction (e.g., isotype control protein, non-target cell line). Library Design: A service provider synthesizes a vast random-sequence oligonucleotide library (typically 10^14 - 10^15 unique sequences) flanked by constant primer regions. 2. The Subtractive SELEX Cycle (Repeated 8-15 Rounds) This is the iterative heart of the service: * a. Negative Selection (Subtraction): The oligonucleotide pool is incubated with the counter-target (or complex background, like serum). Sequences that bind to this unwanted material are discarded. * b. Positive Selection: The unbound sequences from (a) are then incubated with the target of interest. The bound sequences are recovered. * c. Washing: Non-specific or weakly bound sequences are washed away.…
What is CE-SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is the standard process for aptamer development. It involves iterative rounds of selection and amplification to enrich nucleic acid sequences that bind tightly to a target molecule. Traditional SELEX often uses immobilization of the target on beads or filters, which can be slow (8-15 rounds) and may introduce bias by selecting for sequences that bind to the immobilization matrix itself. CE-SELEX uses Capillary Electrophoresis as the separation mechanism. The key principle is that when an aptamer binds to its target, it forms a complex with a different charge-to-size ratio, causing it to migrate at a different time (shifted peak) in the capillary compared to the unbound nucleic acid library. This complex can be isolated and collected with exquisite precision. Core Advantages of a CE-SELEX Screening Service A service provider offering CE-SELEX delivers significant benefits: Extreme Speed and Efficiency: Often requires only 2-4 rounds of selection to obtain high-affinity aptamers (nanomolar to picomolar Kd), compared to many more rounds in traditional SELEX. This translates to weeks or months of time saved. Solution-Phase Selection: The target is free in solution, eliminating immobilization bias. This allows for selection against targets in their native conformation and enables selection for small molecules and…
What is Whole-cell SELEX? Whole-cell SELEX (Systematic Evolution of Ligands by EXponential enrichment) is a technique used to discover aptamers (single-stranded DNA or RNA molecules) that bind specifically to a target living cell. Unlike traditional SELEX that uses a purified protein target, whole-cell SELEX presents the target in its native, complex cellular environment. This allows for the selection of aptamers against: Native cell-surface proteins in their proper folding and post-translational modifications. Complex targets like transmembrane receptors in their natural lipid environment. Unknown surface biomarkers without prior knowledge of the cell's molecular makeup. Specific cell states (e.g., activated, cancerous, infected) based on differences in surface expression. The Core Process: How Whole-cell SELEX Works A professional service will manage this complex, iterative pipeline: Library & Design: Starting with a vast, random synthetic oligonucleotide library (10^14 - 10^15 unique sequences). Positive Selection: Incubating the library with the target cells (e.g., cancer cells, stem cells, bacteria). Aptamers that bind to any surface structure are retained. Counter-Selection (Critical Step): The bound pool is then exposed to non-target or control cells (e.g., healthy cells, a different cell line). Sequences that bind to these are discarded. This step is crucial for generating specificity. Elution & Amplification: Aptamers specifically bound to the target cells are recovered, amplified by PCR…
What is Small Molecule SELEX? SELEX is an iterative in vitro selection process that sifts through a vast random library of nucleic acid sequences (typically 10^13 - 10^15 different molecules) to find the few that bind tightly and specifically to a target. The Challenge with Small Molecules: Low epitope density: Small molecules offer limited surface area for binding, making it hard to find high-affinity aptamers. Immobilization required: They must be attached to a solid support (beads, chip, column) for partitioning, which can mask potential binding sites or introduce non-specific interactions. Negative Selection is Crucial: To avoid selecting aptamers that bind to the immobilization matrix instead of the target. Standard Service Workflow (What the Provider Does): Project Design & Target Immobilization: Consultation: The provider works with you to understand the target's chemistry, desired affinity, and application (e.g., biosensor, therapeutic inhibitor, diagnostic). Conjugation: They chemically conjugate your small molecule to an appropriate carrier (e.g., beads, magnetic particles, agarose resin, or a surface like a chip). This is a critical, proprietary step for many providers. The SELEX Cycle (Repeated 8-15 rounds): Incubation: The vast oligonucleotide library is incubated with the immobilized target. Partitioning: Unbound sequences are washed away. Sequences bound to the target (and unfortunately, sometimes to the matrix) are retained. Elution: Bound…
Core Concept The central idea is "Target-based Drug Discovery." Instead of screening compounds on whole cells or organisms (phenotypic screening), you start with a specific protein (e.g., a kinase, receptor, ion channel) implicated in a disease. Services then help you understand that target and find molecules that modulate it. Categories of Protein Target Services These services typically follow the drug discovery pipeline: 1. Target Identification & Validation Bioinformatics & Omics Analysis: Mining genomic, proteomic, and clinical data to identify novel disease-associated targets. Genetic Validation: CRISPR/Cas9 gene editing (knock-out/knock-in), siRNA/shRNA knockdown to confirm the target's role in disease pathways. Functional Validation: Cell-based assays to see if modulating the target affects disease-relevant phenotypes. 2. Protein Expression & Purification Recombinant Protein Production: Cloning, expressing (in E. coli, insect, or mammalian cells), and purifying milligram to gram quantities of the target protein. This is essential for structural studies and biochemical assays. Membrane Protein Expertise: Specialized services for difficult-to-express targets like GPCRs and ion channels. Tagging & Labeling: Adding tags (His, GST, FLAG) for purification or fluorescent/isotopic labels for assays. 3. Structural Biology & Biophysics X-ray Crystallography: Determining high-resolution 3D structures of protein-ligand complexes. Cryo-Electron Microscopy (Cryo-EM): For large complexes or membrane proteins unsuitable for crystallography. Nuclear Magnetic Resonance (NMR) Spectroscopy: For studying dynamics and ligand binding in solution. Surface…
What is an Aptamer? First, a quick reminder: Aptamers are short, single-stranded DNA or RNA oligonucleotides that bind to a specific target with high affinity and specificity. They are often called "chemical antibodies." The Core Service: SELEX (The Screening Process) The service revolves around executing a SELEX (Systematic Evolution of Ligands by EXponential enrichment) campaign. This is an iterative, in-vitro combinatorial chemistry process that screens a vast random library (10^14 - 10^15 unique sequences) to find the few that bind your target. A standard SELEX workflow includes: Library Design & Synthesis: Creating the initial random oligonucleotide pool. Incubation: The library is exposed to the target. Partitioning: Bound sequences are separated from unbound ones (the most critical step, varying by target type). Amplification: The bound sequences are amplified (usually by PCR for DNA, RT-PCR for RNA). Counter-Selection (Negative Selection): To increase specificity, the pool is exposed to non-target surfaces (e.g., immobilization matrix, related proteins) to remove non-specific binders. Repetition: Steps 2-5 are repeated for 8-15 rounds until a high-affinity pool is enriched. Cloning & Sequencing: The final pool is cloned, and individual aptamer sequences are identified via Next-Generation Sequencing (NGS). Bioinformatics & Analysis: NGS data is analyzed to identify candidate sequences, often clustered into families based on sequence/structure motifs. Characterization: Top candidates…
Aptamer Capture-SELEX Service refers to a specialized, outsourced process where a company or academic core facility performs the entire Capture-SELEX procedure to develop DNA or RNA aptamers for a client's specific target molecule. This is a crucial service for researchers and companies who need high-affinity, specific aptamers but lack the specialized equipment, expertise, or time to run the SELEX process in-house. Let's break down what this service entails. 1. What is Capture-SELEX? First, understand the standard SELEX (Systematic Evolution of Ligands by EXponential enrichment). It's an iterative process to select aptamers from a vast random oligonucleotide library (10^14 - 10^15 different sequences). Capture-SELEX is a specific variant designed primarily for small molecules or targets that are difficult to immobilize directly on a solid support without affecting their structure/function. The Key Difference: Instead of immobilizing the target itself, a short, complementary "capture strand" is immobilized on beads or a surface. The initial ssDNA library is designed with a region complementary to this capture strand. The target is free in solution. How it Works: The library is bound to the surface via the capture strand. The target molecule is introduced in solution. Only library sequences that fold into a structure capable of binding the target will undergo a conformational change. This binding event often weakens or…
What is Live Cell SELEX? Traditional SELEX uses purified target proteins. Live Cell SELEX uses intact, living cells in their native state. This is crucial because: It selects for aptamers that bind to targets in their natural conformation and post-translational modifications (e.g., glycosylation). It inherently selects for cell-specificity (e.g., cancer cell vs. healthy cell) without needing to know the exact molecular target upfront. It can discover aptamers against unknown or membrane-bound targets that are difficult to purify. Core Workflow of a Typical Service A full-service provider will manage the entire pipeline: 1. Project Design & Consultation Target Cell Line Definition: Defining the "positive" cell line (e.g., patient-derived cancer cells, activated immune cells). Counter-Selection Strategy: Choosing the "negative" cell line(s) (e.g., healthy counterpart, isogenic control) to eliminate non-specific binders. Library Design: Recommending or customizing the starting random oligonucleotide library (length, modifications like 2'-F pyrimidines for RNA aptamers for stability). 2. The Selection Phase (The Iterative SELEX Cycles) Incubation: The random library is incubated with the counter-selection cells. Unbound/non-specific sequences are collected. Positive Selection: The pre-cleared library is incubated with the target cells. Cells are washed stringently. Recovery: Cell-bound aptamers are recovered (e.g., by cell lysis, heat elution, or protease treatment). Amplification: Recovered sequences are amplified by PCR (for DNA) or RT-PCR (for…
